in vivo News and Research

RSS

ARPA-H funding boosts Wyss Institute's RNA therapeutic project

With the award for up to $27 million from the Advanced Research Projects Agency for Health (ARPA-H), a collaborative research project at the Wyss Institute for Biologically Inspired Engineering at Harvard University will advance a disease-agnostic novel RNA therapeutic with the potential to treat diverse diseases, and to be effectively and rapidly deployable.

15 Jul 2024

Mogrify appoints Dr. Jonathan Appleby as Chief Scientific Officer

Strategic hire bolsters executive leadership team as Company progresses multiple therapeutic programs toward and into clinical development.

From Mogrify 15 Jul 2024

One-time prime editing targets common genetic cause of cystic fibrosis

Researchers optimized prime editing for the efficient correction of the cystic fibrosis transmembrane conductance regulator F508del mutation in human airway epithelial cells, achieving high correction efficiencies and functional restoration with minimal off-target effects.

15 Jul 2024

Twincretin drug Tirzepatide shows unmatched efficacy in weight loss and diabetes management

Tirzepatide, a novel twincretin drug, significantly improves weight loss and glycemic control in obese and type 2 diabetes patients, outperforming traditional treatments in clinical trials.

15 Jul 2024

New brain targets for GLP1-based obesity drugs may reduce weight without nausea

Researchers identified distinct hindbrain GLP1R neurons driving satiety and aversion, offering new targets for effective, side-effect-free obesity treatments.

14 Jul 2024

Antibody-drug conjugate shows preclinical efficacy

A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, "Entering the golden age for antibody-drug conjugates in gynecologic cancer."

13 Jul 2024

Study identifies RFC4 as key player in nasopharyngeal carcinoma

Lichuan Wu et al., at Medical College of Guangxi University, China, presented a comprehensive study on the role of replication factor C subunit 4 (RFC4) in nasopharyngeal carcinoma (NPC), a type of epithelial cancer commonly associated with Epstein-Barr virus infection.

12 Jul 2024

Novel DNA aptamers of melanopsin developed to regulate circadian rhythm

DNA aptamers of melanopsin that regulate the clock hands of biological rhythms were developed by the Toyohashi University of Technology and the National Institute of Advanced Industrial Science and Technology (AIST) group.

12 Jul 2024

Accelerate Your Research: Dispen3D Harnesses the Power of 3D Models

Dispen3D is setting new standards in single-cell biology, enabling researchers to conduct high-precision experiments that drive advancements in drug discovery, personalized medicine, and regenerative therapies.

From SEED Biosciences 12 Jul 2024

Light-activated drugs: A revolutionary approach in neuropathic pain treatment

Light can be used to activate drugs in specific parts of the body through photopharmacology.

11 Jul 2024

Researchers identify molecular processes crucial for the maturation of Group 2 innate lymphoid cells

Scientists have discovered a novel mechanism of ILC2 immune cell development which may be involved in exacerbating allergic diseases.

11 Jul 2024

Researchers identify shared molecular mechanism in cancer and pregnancy that suppresses immune system

Researchers elucidated the shared immune tolerance mechanisms in cancer and pregnancy, focusing on the role of an immune checkpoint protein as an onco-fetal immune tolerance checkpoint.

11 Jul 2024

New gene editing technique offers hope for millions

A team led by Mass Eye and Ear researchers has demonstrated for the first time a successful restoration of hearing through a novel, in vivo genome editing approach in an adult mouse model with a form of inherited deafness caused by mutations in microRNA.

11 Jul 2024